Details for New Drug Application (NDA): 021320
✉ Email this page to a colleague
The generic ingredient in PLENAXIS is abarelix. Additional details are available on the abarelix profile page.
Summary for 021320
Tradename: | PLENAXIS |
Applicant: | Speciality European |
Ingredient: | abarelix |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INTRAMUSCULAR | Strength | 100MG/VIAL | ||||
Approval Date: | Nov 25, 2003 | TE: | RLD: | No |
Expired US Patents for NDA 021320
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Sign Up | ⤷ Sign Up |
Speciality European | PLENAXIS | abarelix | INJECTABLE;INTRAMUSCULAR | 021320-001 | Nov 25, 2003 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription